Study of Tri-Moxi-Vanc Dropless Therapy (triamcinolone acetonide + moxifloxacin + vancomycin) after cataract surgery published in Current Opinion in Ophthalmology- Imprimis Pharmaceuticals
Imprimis Pharmaceuticals has announced the release of data from a peer-reviewed study of patients receiving Tri-Moxi-Vanc Dropless Therapy (triamcinolone acetonide + moxifloxacin + vancomycin) following cataract surgery. The study evaluated 1,541 eyes from 922 patients and demonstrated that in nearly 92% of cases (n=1413/1541), supplemental medication was not required after surgery.
The study retrospectively reviewed a case series of patients receiving cataract surgery and eligible for a transzonular injection of compounded Tri-Moxi-Vanc (3.0 mg triamcinolone acetonide, 0.2 mg moxifloxacin, 2.0 mg vancomycin). This was a retrospective analysis of the medical records of 922 patients who underwent cataract surgery followed by an injection of TMV from November 2013 through December 2014. The primary analysis consisted of 1,541 surgical cases performed at a single-specialty ambulatory center (SurgiCenter of Vineland, Vineland, New Jersey). The study protocol was approved by the Wills Eye Hospital Institutional Review Board (Philadelphia, Pennsylvania, USA).
Cases were evaluated preoperatively and at postoperative Days 1, 14-21, and 90 for visual acuity, intraocular pressure (IOP), and presence of endophthalmitis, inflammation and cystoid macular edema (CME). The primary findings of the study included no major intraoperative complications associated with the transzonular injection technique, no cases of postoperative endophthalmitis and mean visual acuity was significantly increased at all postoperative visits (P<0.0001), including the day after surgery. in addition, rates of infection and inflammation reported appear similar to reported rates with alternative prophylactic therapies such as topical drops, and the rate of breakthrough inflammation at days 14-21 was 9.2% (n="132/1429).">0.0001),>
Finally, the rate of visually significant postoperative cystoid macular edema was 2.0% (n = 28/1429) and the rate of clinically significant postoperative IOP increase was low: 0.9% (n = 13/1425) of cases had an increase of at least 10 mmHg in IOP at Days 14-21 or 90. Only four of these cases had an IOP over 30 mmHg. Results will be published in the January 2017 print issue of Current Opinion in Ophthalmology.
Related news and insights
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.
The Menarini Group and Radius Health announced positive topline results from the phase III EMERALD study evaluating RAD 1901 (elacestrant) as a monotherapy versus the standard of care (SoC) for the treatment of ER+/HER2- advanced or metastatic breast cancer (mBC).
Gilead Sciences, Inc. announced the FDA approved a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy.